Zacks Research Weighs in on Deciphera Pharmaceuticals, Inc.’s Q1 2025 Earnings (NASDAQ:DCPH)

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) – Zacks Research decreased their Q1 2025 earnings estimates for shares of Deciphera Pharmaceuticals in a report issued on Wednesday, May 1st. Zacks Research analyst A. Chakraborty now expects that the company will post earnings per share of ($0.57) for the quarter, down from their previous estimate of ($0.56). The consensus estimate for Deciphera Pharmaceuticals’ current full-year earnings is ($2.16) per share. Zacks Research also issued estimates for Deciphera Pharmaceuticals’ Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($2.02) EPS and Q1 2026 earnings at ($0.38) EPS.

DCPH has been the topic of a number of other research reports. JPMorgan Chase & Co. lifted their price target on Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the company a “neutral” rating in a report on Wednesday, March 20th. Guggenheim reaffirmed a “neutral” rating on shares of Deciphera Pharmaceuticals in a research note on Tuesday, April 30th. Jefferies Financial Group reaffirmed a “hold” rating and set a $25.60 target price (down previously from $26.00) on shares of Deciphera Pharmaceuticals in a research report on Monday, April 29th. JMP Securities reaffirmed a “market perform” rating on shares of Deciphera Pharmaceuticals in a report on Tuesday, April 30th. Finally, Jonestrading restated a “hold” rating and issued a $25.60 price target on shares of Deciphera Pharmaceuticals in a research report on Monday, April 29th. Seven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $24.17.

Deciphera Pharmaceuticals Stock Up 0.0 %

Shares of NASDAQ DCPH opened at $25.38 on Monday. The business has a fifty day simple moving average of $16.91 and a 200-day simple moving average of $15.07. The company has a market cap of $2.09 billion, a price-to-earnings ratio of -11.08 and a beta of 0.20. Deciphera Pharmaceuticals has a 12 month low of $9.90 and a 12 month high of $25.47.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its earnings results on Tuesday, February 6th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.04. The business had revenue of $48.30 million during the quarter, compared to analysts’ expectations of $45.93 million. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. The company’s quarterly revenue was up 32.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.60) earnings per share.

Hedge Funds Weigh In On Deciphera Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in DCPH. Inspire Investing LLC increased its position in shares of Deciphera Pharmaceuticals by 10.4% in the 3rd quarter. Inspire Investing LLC now owns 27,532 shares of the company’s stock valued at $350,000 after buying an additional 2,583 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Deciphera Pharmaceuticals by 96.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 2,026 shares of the company’s stock worth $26,000 after acquiring an additional 997 shares in the last quarter. Panagora Asset Management Inc. acquired a new stake in shares of Deciphera Pharmaceuticals during the third quarter worth about $1,167,000. Principal Financial Group Inc. lifted its holdings in shares of Deciphera Pharmaceuticals by 10.3% during the 3rd quarter. Principal Financial Group Inc. now owns 18,266 shares of the company’s stock valued at $232,000 after purchasing an additional 1,699 shares in the last quarter. Finally, Fox Run Management L.L.C. bought a new position in shares of Deciphera Pharmaceuticals during the 3rd quarter valued at about $287,000. 70.96% of the stock is owned by institutional investors.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.